TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Two reviews found no clearly detectable increase in most adverse maternal or perinatal outcomes after GLP-1 drug exposure around conception or early pregnancy. The studies do not establish safety, and researchers say current advice to stop treatment before planned conception remains unchanged.
Two reviews of GLP-1 receptor agonists used around conception or early pregnancy found no clearly detectable increase in most measured adverse outcomes, but researchers said the findings do not establish that the drugs are safe during pregnancy. The evidence offers limited information about inadvertent exposure while current advice to stop treatment before planned conception remains unchanged.
A systematic review and meta-analysis of 10 studies covering more than 2.1 million pregnancies found no clear rise in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, fetal growth concerns, or excess gestational weight gain among women exposed to GLP-1 drugs in the periconceptional period. The review’s pooled estimate for preeclampsia was lower among exposed women, but that result came from only two datasets and the authors said it should be interpreted cautiously.
A second review, presented at the European Association for the Study of Diabetes annual meeting and published in Lancet Obstetrics, Gynaecology, & Women’s Health, examined data on more than 40,000 women, primarily with type 2 diabetes. Across four studies, stopping GLP-1 drugs during the first trimester was not associated with a higher rate of congenital anomalies (risk ratio 1.02, 95% CI 0.96–1.08). Across two studies, early pregnancy loss was more common among exposed women, but the largest contributing study combined miscarriages and terminations, making that finding difficult to interpret.
The reviews have different populations and measures, and their findings should not be read as proof of safety. The first review noted differences in how exposure was defined, possible residual confounding, and few studies for several outcomes. GLP-1 drugs are not approved for use during pregnancy; labeling advises stopping them at least two months before planned conception.
Guidance Remains Cautious
The findings concern people who may have taken a GLP-1 drug before realizing they were pregnant. The first review’s authors said the results may provide limited reassurance after inadvertent exposure before conception or early in pregnancy. They also said the findings should not be taken as support for continuing treatment during pregnancy.
People using these medicines to manage diabetes or another approved indication can discuss treatment decisions with clinicians when planning pregnancy. The source report says current recommendations to discontinue GLP-1 receptor agonists before conception should remain in place until more robust evidence is available. The reviews do not establish what risk, if any, applies to a particular drug, dose, or duration of exposure.
Evidence and Existing Advice
GLP-1 drugs have grown in use and in the number of conditions for which they are prescribed. As that use expands, the source report’s authors said inadvertent exposure around conception and early pregnancy has likely increased. Yet human pregnancy data remain limited, which is one reason drug labeling advises stopping treatment at least two months before planned conception.
The second review’s authors also produced an international consensus statement on GLP-1 use before, during, and after pregnancy in women with diabetes. Claire Meek of the University of Leicester said the guidance proposes clinical targets and strategies to help women understand when and how to stop treatment safely. She said contraception is strongly recommended while taking GLP-1 drugs and that treatment should stop in early pregnancy if conception occurs.
“The results “may provide limited reassurance following inadvertent exposure before conception or during early pregnancy, but they should not be interpreted as supporting continued treatment during pregnancy.””
— Asma Khalil, MD, MSc, and colleagues
Limits of Pregnancy Data
The reviews cannot rule out risks that the available studies were too limited to detect. The first analysis identified variation in exposure definitions and possible residual confounding, and some outcomes were supported by only a small number of studies. The results also do not show whether current prescribing patterns produce the same outcomes as the past practice represented in the data.
The early pregnancy loss finding in the second review remains hard to interpret because miscarriage and termination were combined in the largest contributing study. Evidence is also scarce on GLP-1 use in type 1 diabetes, gestational diabetes, and during lactation. The source material does not specify when the meeting took place or provide detailed recommendations for each medication and exposure timeline.
Research and Clinical Guidance
For now, the first review’s authors say recommendations to stop GLP-1 receptor agonists before planned conception should remain unchanged. Meek said the consensus statement recommends contraception during treatment and stopping the medicine if pregnancy occurs. People planning pregnancy or who become pregnant while taking one of these drugs can discuss treatment with a qualified clinician.
The researchers called for more investment in women’s health research, regulatory changes that allow evidence to be generated while protecting women and unborn children, and mandatory reporting of sex-disaggregated data. Further studies will be needed to clarify risks by drug, timing, and outcome, as well as to address evidence gaps around type 1 diabetes and breastfeeding.
Key Questions
Do these studies prove GLP-1 drugs are safe during pregnancy?
No. The reviews found no clear increase in most measured outcomes, but the researchers said the evidence does not establish safety and remains limited.
What should someone do if they become pregnant while taking a GLP-1 drug?
The consensus statement described in the report advises stopping treatment in early pregnancy. Contact a qualified clinician promptly to discuss the medicine and next steps.
How long before planned conception should treatment stop?
Drug labeling recommends stopping GLP-1 receptor agonists at least two months before planned conception, according to the source report.
What did the second review find about early pregnancy loss?
It reported a higher rate among women exposed to GLP-1 drugs, but interpretation is difficult because the largest contributing study combined miscarriages and terminations.
Source: rss
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
